Oncotarget


2022 Press Releases

Oncotarget | Site of Analysis Matters - Ongoing Complete Response to Nivolumab in Patient With HIV/HPV Related Metastatic Anal Cancer and MLH1 Mutation


FOR IMMEDIATE RELEASE
2022-09-29

This case report represents an HIV infected patient with anal cancer, MSI high status, a high mutation frequency regarding tumor mutational burden (TMB), and an ongoing response to Nivolumab.


BUFFALO, NY - 
September 29, 2022 – A new research paper was published in Oncotarget's Volume 13 on September 14, 2022, entitled, “Site of analysis matters - Ongoing complete response to Nivolumab in a patient with HIV/HPV related metastatic anal cancer and MLH1 mutation.”

Anal cancer is a rare disease... continue reading >>

Oncotarget | Targeting Krebs-cycle-deficient RCC with Poly ADP-ribose Polymerase Inhibitors, Low-dose Alkylating Chemotherapy


FOR IMMEDIATE RELEASE
2022-09-20

“In this study, we sought to examine the activity of combined TMZ and PARPi in Krebs-cycle-deficient renal cancer models.”

BUFFALO, NY - September 20, 2022 – A new research paper was published in Oncotarget's Volume 13 on September 14, 2022, entitled, “Targeting Krebs-cycle-deficient renal cell carcinoma with Poly ADP-ribose polymerase inhibitors and low-dose alkylating chemotherapy.

Loss-of-function mutations in genes encoding the Krebs cycle enzymes Fumarate Hydratase (FH) and Succinate... continue reading >>

Oncotarget | An ABC Transporter as Potential Target Against SHH-Medulloblastoma: From Benchtop to Bedside


FOR IMMEDIATE RELEASE
2022-09-15

“The discovery of novel modulators of the SHH pathway to advance SHH-MB treatment is greatly needed.”

 


BUFFALO, NY- September 15, 2022 – A new editorial paper was published in Oncotarget on September 8, 2022, entitled, “An ABC transporter as a potential target against SHH-Medulloblastoma: From Benchtop to Bedside.”

Medulloblastoma (MB) is a common malignant pediatric brain tumor divided into four main subgroups (WNT, SHH, Group 3 and 4). The most prevalent MB in children <3 years is the Sonic ... continue reading >>

Oncotarget | Targeted Elastin-like Polypeptide Fusion Protein for Near-infrared Imaging of Human and Canine Urothelial Carcinoma


FOR IMMEDIATE RELEASE
2022-09-08

“We have developed a peptide-based NIR probe, Cy5.5-N24-EGF, that shows high EGFR-specific binding specificity in canine and human UC in vitro and ex vivo.”

 


BUFFALO, NY- September 8, 2022 –
A new research paper was published in Oncotarget on September 6, 2022, entitled, “Targeted elastin-like polypeptide fusion protein for near-infrared imaging of human and canine urothelial carcinoma.”

Bladder cancer (BC) is the 10th most common malignancy, affecting more than half a million people worldwide... continue reading >>

Oncotarget | Kinase Activity Profiling in Renal Cell Carcinoma, Benign Renal Tissue and in Response to Four Different Tyrosine Kinase Inhibitors


FOR IMMEDIATE RELEASE
2022-08-17

“Thus, the presented findings might provide options to select the most promising TKI for individual RCC patients prior to initiation of TKI-therapies.”

BUFFALO, NY- August 17, 2022 – A new research paper was published in Oncotarget on August 4, 2022, entitled, “Kinase activity profiling in renal cell carcinoma, benign renal tissue and in response to four different tyrosine kinase inhibitors.”

Kinase activity is frequently altered in renal cell carcinoma (RCC), and tyrosine kinase inhibitors... continue reading >>

Oncotarget | Glypican-3 (GPC3) Associated With MCPyV-negative Status and Impaired Outcome in Merkel Cell Carcinoma


FOR IMMEDIATE RELEASE
2022-08-11

“High prevalence of surface GPC3 makes it a putative drug target.”

BUFFALO, NY- August 11, 2022 – A new research paper was published in Oncotarget on August 3, 2022, entitled, “Glypican-3 (GPC3) is associated with MCPyV-negative status and impaired outcome in Merkel cell carcinoma.”

Merkel cell carcinoma (MCC) is an aggressive skin cancer, related to the Merkel Cell Polyomavirus (MCPyV) in 80% of cases. Immune checkpoint inhibitors provide sustained benefit in about 50% of MCC patients with... continue reading >>

Oncotarget | A Novel Mechanism of Regulation of the Oncogenic Transcription Factor GLI3 by Toll-like Receptor Signaling


FOR IMMEDIATE RELEASE
2022-08-09

“These results increase our understanding of the signaling molecules that can regulate GLI3 in a HH-independent manner.”


BUFFALO, NY- August 9, 2022 –
A new research paper was published in Oncotarget on August 3, 2022, entitled, “A novel mechanism of regulation of the oncogenic transcription factor GLI3 by toll-like receptor signaling.”

The transcription factor GLI3 is a member of the GLI family and has been shown to be regulated by canonical hedgehog (HH) signaling through smoothened (SMO).... continue reading >>

Oncotarget | Chemoradiation-induced Alteration of Programmed Death-ligand 1, CD8+ Tumor-infiltrating Lymphocytes and Mucin Expression in Rectal Cancer


FOR IMMEDIATE RELEASE
2022-08-02

“In conclusion, our study provides further data on the immunologic impact of nCRT in rectal cancer.”


BUFFALO, NY- August 2, 2022 – A new research paper was published in Oncotarget on July 28, 2022, entitled, “Chemoradiation-induced alteration of programmed death-ligand 1, CD8+ tumor-infiltrating lymphocytes and mucin expression in rectal cancer.”

DNA damage and resulting neoantigen formation is considered a mechanism for synergy between radiotherapy and PD-1/PD-L1 pathway inhibition to induce... continue reading >>

Oncotarget | CUDC907 Promotes Apoptosis of NF2 Schwannoma Cells


FOR IMMEDIATE RELEASE
2022-07-26

“CUDC907 has cytotoxic activity in NF2 schwannoma models and primary VS cells and is a candidate for clinical trials.”



BUFFALO, NY- July 26, 2022 –
A new research paper was published in Oncotarget on July 19, 2022, entitled, “CUDC907, a dual phosphoinositide-3 kinase/histone deacetylase inhibitor, promotes apoptosis of NF2 Schwannoma cells.”

Neurofibromatosis Type 2 (NF2) is a rare tumor disorder caused by pathogenic variants of the merlin tumor suppressor encoded by NF2. Patients develop... continue reading >>

Oncotarget | Predicting Cancer Immunotherapy Response From Gut Microbiomes Using Machine Learning Models


FOR IMMEDIATE RELEASE
2022-07-19

“Findings demonstrate how machine learning models can reveal microbiome-immunotherapy interactions that may ultimately improve cancer patient outcomes.”


BUFFALO, NY- July 19, 2022 –
A new research paper was published in Oncotarget on July 19, 2022, entitled, “Predicting cancer immunotherapy response from gut microbiomes using machine learning models.”

“In the last decade, the use of cancer immunotherapy targeting immune checkpoint inhibitors (ICIs) to boost T cell mediated cancer cell... continue reading >>

Oncotarget | Role of Germline Variants in the Metastasis of Breast Carcinomas


FOR IMMEDIATE RELEASE
2022-07-07

“We found several gene candidates through which the host’s genetic makeup contributes to metastasis.”


BUFFALO, NY- July 7, 2022 – A new research paper was published in Oncotarget on June 30, 2022, entitled, “Role of germline variants in the metastasis of breast carcinomas.”

Most cancer-related deaths in breast cancer patients are associated with metastasis, a multistep, intricate process that requires the cooperation of tumor cells, tumor microenvironment and metastasis target tissues. It is... continue reading >>

Oncotarget | Continuous Treatment With Abemaciclib Leads to Sustained and Efficient Inhibition of Breast Cancer Cell Proliferation


FOR IMMEDIATE RELEASE
2022-07-06

"These preclinical results support the unique efficacy and safety profile of abemaciclib observed in clinical trials."


BUFFALO, NY- July 6, 2022 –
Researchers from
Eli Lilly and Company published a new research paper in Oncotarget on July 2, entitled, “Continuous treatment with abemaciclib leads to sustained and efficient inhibition of breast cancer cell proliferation.”

 

Worldwide, breast cancer (BC) is the second most common cancer. Pharmacologically targeting cyclin-dependent kinase 4 and 6... continue reading >>

Oncotarget | Impact Journals Sponsors 2022 Ride for Roswell


FOR IMMEDIATE RELEASE
2022-06-14

Impact Journals is sponsoring Team Open Access on June 25, 2022, in the annual cycling event to end cancer: The Ride for Roswell.

BUFFALO, NY- June 14, 2022 – The Ride for Roswell is one of the nation’s largest cycling events—hosted by Roswell Park Comprehensive Cancer Center—to raise awareness and funds for cancer research and patient care. This charity bike ride, based out of Buffalo, New York, has brought people together for 26 years to celebrate cancer survivors, pay tribute to lives that... continue reading >>

Oncotarget | A novel group of genes that cause endocrine resistance in breast cancer identified by dynamic gene expression analysis


FOR IMMEDIATE RELEASE
2022-06-08

“Our findings identify 34 novel genes for further study as potential therapeutic targets for treatment of endocrine-resistant BC and TNBC.”


BUFFALO, NY- June 8, 2022 –
A research paper was recently published in Oncotarget, entitled, “A novel group of genes that cause endocrine resistance in breast cancer identified by dynamic gene expression analysis.”
 

Breast cancer (BC) is the most common type of cancer diagnosed in women. Among female cancer deaths, BC is the second leading cause of death... continue reading >>

Oncotarget | NF-κB Over-Activation Portends Improved Outcomes in HPV-Associated Head and Neck Cancer


FOR IMMEDIATE RELEASE
2022-05-25

“Since clinicians are exploring therapeutic deintensification for HPV+ HNSCC, identifying patients with good or poor prognosis using the NF-κB Activity Classifier may be useful to guide therapeutic decisions.”


BUFFALO, NY- May 25, 2022 –
A new research paper was published in Oncotarget, entitled, “NF-κB over-activation portends improved outcomes in HPV-associated head and neck cancer.”

Head and neck squamous cell carcinoma (HNSCC) is a devastating disease that impairs fundamental tissues involved
... continue reading >>

Oncotarget | Anti-Cancer Drug Profiling With CancerOmicsNet


FOR IMMEDIATE RELEASE
2022-05-19

A new research paper was published in Volume 13 of Oncotarget, entitled, “CancerOmicsNet: a multi-omics network-based approach to anti-cancer drug profiling.”


BUFFALO, NY- May 19, 2022 –
A new research paper was published in Volume 13 of Oncotarget, entitled, “CancerOmicsNet: a multi-omics network-based approach to anti-cancer drug profiling.”

Researchers from Louisiana State University developed CancerOmicsNet—a graph neural network model to predict the growth rate of a cancer cell line after... continue reading >>

Impact Journals to Present Scientific Integrity Process at 2022 SSP Annual Meeting


FOR IMMEDIATE RELEASE
2022-05-16

Impact Journals is a supporter and exhibitor at the Society for Scholarly Publishing (SSP) 44th Annual meeting—taking place from June 1–3, 2022, at the Sheraton Grand Chicago Riverwalk in Chicago.


BUFFALO, NY-May 16, 2022
Impact Journals (based out of Buffalo, New York) is an international open-access publisher of journals in the field of biomedical sciences. Impact Journals is on a mission to provide scientists with the opportunity to share exceptional discoveries, offer services that enable ... continue reading >>

Oncotarget: Mutational Burden in Lung Cancer Studied in Multisite Cohort


FOR IMMEDIATE RELEASE
2022-04-25

In a trending new research paper published in Oncotarget, researchers conducted a multi-site cohort study of tumor mutational burden among hundreds of patients diagnosed with stage IV non-small cell lung cancer.

 

BUFFALO, NY-April 25, 2022 – A new research paper, entitled, “Real-world survival analysis by tumor mutational burden in non-small cell lung cancer: a multisite U.S. study,” was published in Oncotarget on January 31, 2022, by researchers from University of Utah, University of... continue reading >>

Open-Access Oncotarget Shifts to Continuous Publishing


FOR IMMEDIATE RELEASE
2022-01-06

As of 2022, the peer-reviewed and open-access journal Oncotarget has shifted to continuous publishing.

 

 

Listen to an audio version of this announcement

 

 

 

BUFFALO, NY, January 6, 2022 – Since its inception in 2010, Oncotarget has operated ... continue reading >>



Copyright © 2022 Impact Journals, LLC
Impact Journals is a registered trademark of Impact Journals, LLC